With a full and predictable nerve block, a quick onset, and few problems, spinal anaesthesia is a popular option for caesarean deliveries. The quality, duration, and side effects of anaesthesia are improved with the administration of various intrathecal adjuvants. This analysis of medical data involved 62 patients who had spinal anaesthesia used during caesarean deliveries. In this retrospective analysis, we evaluated 62 patients who received hyperbaric bupivacaine (0.5%, 10 mg) and dexmedetomidine (10 µg) in group 1 (n=31) and bupivacaine (0.5%, 10 mg) and sufentanil (5 µg) in group 2 (n=31). Difference in the postoperative pain, motor and sensory block, unfavourable effects within the first 24 hours after delivery, and neonatal outcomes were measured in these two groups. The sufentanil group required much less analgesia than the dexmedetomidine group. According to the VAS scale, postoperative pain in G1 was more severe than in G2. There were no obvious variations in intraoperative sensory and motor block, motor recovery times, or neonatal Apgar ratings between two groups. Shivering was only noticed in G2. The dexmedetomidine group did not experience itchiness or shivering. The sufentanil group had better postoperative analgesia, although there were more side effects overall. Dexmedetomidine used as an adjuvant stopped postoperative shaking. Contrary to what has been reported in the literature, dexmedetomidine does not produce greater or equivalent analgesia to sufentanil.

With a full and predictable nerve block, a quick onset, and few problems, spinal anaesthesia is a popular option for caesarean deliveries. The quality, duration, and side effects of anaesthesia are improved with the administration of various intrathecal adjuvants. This analysis of medical data involved 62 patients who had spinal anaesthesia used during caesarean deliveries. In this retrospective analysis, we evaluated 62 patients who received hyperbaric bupivacaine (0.5%, 10 mg) and dexmedetomidine (10 µg) in group 1 (n=31) and bupivacaine (0.5%, 10 mg) and sufentanil (5 µg) in group 2 (n=31). Difference in the postoperative pain, motor and sensory block, unfavourable effects within the first 24 hours after delivery, and neonatal outcomes were measured in these two groups. The sufentanil group required much less analgesia than the dexmedetomidine group. According to the VAS scale, postoperative pain in G1 was more severe than in G2. There were no obvious variations in intraoperative sensory and motor block, motor recovery times, or neonatal Apgar ratings between two groups. Shivering was only noticed in G2. The dexmedetomidine group did not experience itchiness or shivering. The sufentanil group had better postoperative analgesia, although there were more side effects overall. Dexmedetomidine used as an adjuvant stopped postoperative shaking. Contrary to what has been reported in the literature, dexmedetomidine does not produce greater or equivalent analgesia to sufentanil.